Camarda, Floriana
 Distribuzione geografica
Continente #
EU - Europa 175
NA - Nord America 172
AS - Asia 97
AF - Africa 2
Totale 446
Nazione #
US - Stati Uniti d'America 168
IT - Italia 68
SG - Singapore 48
CN - Cina 25
SE - Svezia 22
IE - Irlanda 18
FI - Finlandia 16
DE - Germania 14
ID - Indonesia 13
AT - Austria 12
FR - Francia 8
CA - Canada 4
GB - Regno Unito 4
IN - India 4
KR - Corea 4
NL - Olanda 4
RU - Federazione Russa 3
CH - Svizzera 2
CI - Costa d'Avorio 2
TH - Thailandia 2
BE - Belgio 1
GR - Grecia 1
HU - Ungheria 1
LT - Lituania 1
TR - Turchia 1
Totale 446
Città #
Singapore 37
Ashburn 36
Chandler 27
Rome 22
Dublin 18
Helsinki 15
Jakarta 13
New York 12
Vienna 12
Milan 11
Chicago 8
Beijing 7
Washington 6
Amsterdam 4
Bari 4
Munich 4
New Haven 4
Toronto 4
Asti 3
Busto Arsizio 3
Falkenstein 3
Jeju City 3
Los Angeles 3
Moscow 3
Paris 3
Princeton 3
Wilmington 3
Abidjan 2
Bangkok 2
Boston 2
Guidonia Montecelio 2
Legnano 2
London 2
Marseille 2
Menlo Park 2
Mumbai 2
Nave 2
Osimo 2
Piacenza 2
Ann Arbor 1
Antwerp 1
Boydton 1
Bremen 1
Budapest 1
Cambridge 1
Dortmund 1
Fairfield 1
Frankfurt am Main 1
Houston 1
Lappeenranta 1
Mechelen 1
Molfetta 1
Phoenixville 1
Piraeus 1
Pune 1
Puyang Chengguanzhen 1
Saint-maur-des-fossés 1
San Diego 1
San Mateo 1
Santa Clara 1
Seattle 1
Shanghai 1
Suyeong-gu 1
Suzhou 1
Tappahannock 1
Woodbridge 1
Xi'an 1
Zhengzhou 1
Totale 324
Nome #
Management of single pulmonary metastases from colorectal cancer: State of the art 73
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation 64
Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report 61
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 38
PARP Inhibitors Resistance: Mechanisms and Perspectives 34
Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids 33
Recent progress in the use of pharmacotherapy for endometrial cancer 29
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 28
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 27
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 24
Advanced and recurrent endometrial cancer: State of the art and future perspectives 22
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 17
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 13
Totale 463
Categoria #
all - tutte 3.463
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.463


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219 0 0 0 0 0 0 0 0 8 0 1 0
2021/202237 1 0 0 3 1 0 1 2 0 5 16 8
2022/2023132 15 11 7 15 7 11 10 6 10 12 19 9
2023/2024190 3 30 18 22 9 26 27 4 4 8 20 19
2024/202595 8 4 36 6 21 20 0 0 0 0 0 0
Totale 463